https://seekingalpha.com/article/4677454-cytomx-therapeutics-inc-ctmx-q4-2023-earnings-call-transcript?source=feed_sector_transcripts
Mar 11, 2024 - CytomX Therapeutics, Inc. (NASDAQ:NASDAQ:CTMX) Q4 2023 Results Conference Call March 11, 2024 5:00 PM ETCompany ParticipantsChris Ogden - Senior Vice...
0
sa:-4518843593058648772
0
https://www.zacks.com/stock/news/2192314/astrazeneca-azn-to-discontinue-two-studies-on-lokelma?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2192314
Dec 01, 2023 - Owing to increased enrollment timelines and low event rates, AstraZeneca (AZN) plans to stop the STABILIZE-CKD and DIALIZE-Outcomes phase III evidence studies for the hyperkalemia drug Lokelma.
zc:7666228982501549482
0
https://www.zacks.com/stock/news/2193518/vanda-vnda-rises-as-fda-accepts-nda-for-gastroparesis-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193518
Dec 05, 2023 - The FDA accepts Vanda's (VNDA) new drug application ("NDA") for tradipitant for treating the symptoms of gastroparesis. The company's shares rise in after-hours trading.
zc:2820871868858812633
0
https://www.zacks.com/stock/news/2193345/is-it-a-good-idea-to-invest-in-ac-immune-aciu-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2193345
Dec 05, 2023 - Here, we discuss some reasons why investing in AC Immune (ACIU) stock now may turn out to be a prudent move.
zc:-2496330855438267457
0
https://www.zacks.com/stock/news/2196713/sanofi-sny-terminates-pompe-disease-deal-as-ftc-objects?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196713
Dec 12, 2023 - Sanofi (SNY) decides to end the licensing deal with Maze Therapeutics for MZE001, a phase II ready oral tablet for Pompe disease, due to the FTC's decision to block the deal.
zc:4083075658357571141
0
https://www.zacks.com/stock/news/2209718/emergent-ebs-gets-235-8m-dod-contract-for-anthrax-vaccine?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2209718
Jan 12, 2024 - Emergent (EBS) signs a deal with the U.S. Department of Defense to supply its anthrax vaccine initially for a five-year period, with an option to extend it for another five years.
zc:848950683659506592
0
https://www.zacks.com/stock/news/2211548/aclaris-acrs-stock-rises-on-appointment-of-new-interim-ceo?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2211548
Jan 17, 2024 - Aclaris (ACRS) appoints Neal Walker as interim CEO after current CEO, Douglas Manion, steps down from his role. Shares rise.
zc:-6600895409325080549
0
https://www.zacks.com/stock/news/2212386/maia-soars-20-on-interim-results-from-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2212386
Jan 18, 2024 - MAIA Biotechnology (MAIA) reports updated results from a mid-stage study. Patients treated with its lead drug achieved disease control rates that were well-sustained compared with previous scans.
zc:-5634115568131083711
0
https://www.zacks.com/stock/news/2212290/is-it-a-good-idea-to-invest-in-intellia-ntla-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2212290
Jan 18, 2024 - Here, we discuss some reasons why investing in Intellia (NTLA) stock now may turn out to be a more prudent move than ever.
zc:6966983953777213566
0
https://www.zacks.com/stock/news/2213010/transcode-rnaz-down-50-on-issue-of-new-common-stock?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2213010
Jan 19, 2024 - TransCode Therapeutics (RNAZ) will issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $7.5 million in gross proceeds from this issue.
zc:-5975565043209740877
0